Mice were humanely killed by CO
2 asphyxiation. A midline incision that included splitting the sternum was made into the abdominal and thoracic cavities. Thoracic aortas were excised and placed in ice-cold PBS. After thorough removal of blood and fibroadipose tissue, the aortas were cross-sectioned into 1 mm-long rings (approximately 12–16 rings per mouse aorta). The rings were placed in a 48-well tissue culture dish containing 400 μL endothelial basal medium-2 (Lonza GmbH, Wuppertal, Germany) supplemented with 0.25% fibrinogen and 0.5% ε-amino-n-caproic acid (Sigma Chemical Co.). Per well, 0.05 U thrombin (Calbiochem, La Jolla, CA) was added, and the gel was allowed to clot at 37°C, 5% CO
2, for 30 minutes. An equal volume of EBM medium (Lonza GmbH, Wuppertal, Germany) was added. In some assays, EBM was supplemented with purchasable recombinant VEGF (rVEGF; R&D Systems GmbH, Wiesbaden, Germany) or rTIMP3 (EMD Chemicals, San Diego, CA). In addition, rTIMP1, rTIMP2, rTIMP3, N-terminal rTIMP3 (aa 1–121), C-terminal rTIMP3 (aa 122–188), and rTIMP4 were expressed in
Escherichia coli with a C-terminal hexahistidine tag and purified from inclusion bodies by a Ni-NTA agarose column. Protein refolding was achieved by dropwise addition of 1 mL denatured protein to 100 mL refolding buffer (100 mM Tris-HCl, 1 M arginine, 100 mM NaCl, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, pH 8.0) at 4°C. Recombinant proteins were used in angiogenesis assays at a concentration of 2 μg/mL. VEGFR2 inhibitor ZM323881 was obtained from Merck Biosciences (Darmstadt, Germany). Aortic rings were kept at 37°C and 5% CO
2 for 6 days with a medium change once at day 3. Quantification of angiogenesis was performed on day 6. Aortic rings were photographed, and the number of microvessels, including branches, was counted as described.
26 Each set of experiments was repeated three times.